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MicroRNAs play important roles in cell dif-
ferentiation by acting as translational inhib-
itors of specific target genes. Here we show
that human granulocytic differentiation is
controlledby a regulatory circuitry involving
miR-223 and two transcriptional factors,
NFI-A and C/EBPa. The two factors com-
pete for binding to the miR-223 promoter:
NFI-A maintains miR-223 at low levels,
whereas its replacement by C/EBPa, fol-
lowing retinoic acid (RA)-induced differenti-
ation, upregulatesmiR-223 expression. The
competition by C/EBPa and the granulo-
cytic differentiation are favored by a nega-
tive-feedback loop in which miR-223 re-
presses NFI-A translation. In line with this,
both RNAi against NFI-A and ectopic ex-
pression of miR-223 in acute promyelocytic
leukemia (APL) cells enhance differentia-
tion, whereas miR-223 knockdown inhibits
the differentiation response to RA. Alto-
gether, our data indicate thatmiR-223 plays
a crucial role during granulopoiesis and
point to the NFI-A repression as an impor-
tant molecular pathway mediating gene re-
programming in this cell lineage.
INTRODUCTION
In the last few years, a new network of regulatory circuitries
operating at the posttranscriptional level has been disclosed
with the discovery of a complex class of noncoding RNAs of
microscopic size (miRNAs). These molecules play a vital rolein plants and animals, mainly by controlling translation and
stability of specific target mRNAs (reviewed in Bartel,
2004). Their function has been correlated with many com-
plex cellular circuitries (Ambros, 2004), and a role in onco-
genesis has also been proposed (Meltzer, 2005). While
some miRNAs show ubiquitous expression, others are lim-
ited to certain stages in development or to certain tissues
and cell types (Pasquinelli et al., 2005). The study of tissue-
specific miRNAs will therefore provide important clues for
identifying new sets of genes and regulatory circuitries in-
volved in the control of cell-specific differentiation.
Hematopoiesis is a life-long, highly regulated multistage
process wherein a pluripotent self-renewing hematopoietic
stem cell (HSC) gives rise to all blood cell lineages. Therefore,
blood cell formation is one of the most suitable systems to
study the molecular mechanisms that control cell differentia-
tion. A recent study has identified three miRNAs preferen-
tially expressed in murine hematopoietic tissues: miR-181,
miR-142, and miR-223 (Chen et al., 2004). miR-181 is
strongly expressed in the thymus, miR-142 in all hematopoi-
etic tissues, and miR-223 in the bone marrow. Interestingly,
ectopic expression of miR-181 in mouse hematopoietic pre-
cursor cells was shown to lead to an increased fraction of B
lineage cells (Chen et al., 2004).
Acute myeloid leukemias (AMLs) represent the clonal ex-
pansion of hematopoietic precursors blocked at different
stages of erythroid, granulocytic, monocytic, or megakaryo-
cytic differentiation (Tenen, 2003). In the acute promyelocytic
leukemia (APL), an AML subtype, the block of differentiation
occurs at the level of promyelocytic precursors. APL is char-
acterized by specific chromosomal translocations involving
the retinoic-acid receptor a (RARa) and creating RARa fusion
genes (Melnick and Licht, 1999; Di Croce et al., 2002). At
physiological levels of retinoids, the PML/RARa fusion protein
causes the block of differentiation and neoplastic transforma-
tion of APL blasts by disrupting the function of PML and re-
pressing transcription of genes regulated by RARa, through
an aberrant recruitment of histone deacetylases and DNA-
methyltransferase activities. Pharmacological doses of RA
can instead overcome this block and induce terminalCell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc. 819
Figure 1. Northern Analysis of miRNA Expression in Different Primary and Clonal Hematopoietic Cells
Total RNA was analyzed by Northern blot with the probes indicated on the side of each panel.
(A) Three micrograms of RNA from CD34+, CD34, and mononucleated cells from peripheral blood (lane MNC) analyzed in parallel to 5 mg of RNA from
mature T (lane T) and committed B lymphoid (lane B) cells.
(B) Three micrograms of RNA from the peripheral blood of a newly diagnosed APL patient (N1) treated for 24 and 72 hr with pharmacological doses of RA,
analyzed in parallel to 3 mg of RNA from blasts of a second patient (N2) that were put in culture and treated with RA for the indicated times.
(C) Five micrograms of RNA from untreated NB4 cells (lanes NB4) or from the same cells treated with RA for 72 hr (lane NB4 + RA) analyzed in parallel to 5 mg
of RNA from HeLa cells.
(D) Five micrograms of RNA from the indicated cell lines; NB4-MR4 and HL60-R are the RA-resistant derivatives of NB4 and HL60 respectively.
(E) Five micrograms of RNA from NB4 and HL60 cells treated with vitamin D3 (lanes +) or analyzed in parallel to 5 mg RNA from untreated cells (lanes). U2
and U6 are control hybridizations to the endogenous corresponding snRNAs.differentiation of PML/RARa-positive APL blasts in vitro and
in vivo (Melnick and Licht, 1999; Lo Coco et al., 2002). Among
the target genes of PML/RARa are included the members of
the family of the CCAAT enhancer proteins (C/EBPs), known
to regulate cell growth and differentiation of many cell types,
including myeloid cells (Wang et al., 1999; McKnight, 2001;
Khanna-Gupta et al., 2001). In particular, C/EBPa is acti-
vated in early myeloid precursors and directs them to granu-
locytic maturation (Radomska et al., 1998; Tenen, 2003).
Loss of C/EBPa functions has been linked to leukemogene-
sis, suggesting an important role for C/EBPa as a tumor sup-
pressor (Pabst et al., 2001; Gombart et al., 2002). PML/RARa
was shown to block C/EBPa activity and inhibit expression of
C/EBP3; interestingly, both of these effects are reverted by
RA treatment (Lodie, et al., 1999; Park et al., 1999).
In this study, we identify as a new C/EBPa target the
miR-223 gene, which undergoes a specific activation during
granulocytic differentiation. Remarkably, one of the putative
targets of miR-223 identified by computational analysis
(Lewis et al., 2005; Krek et al., 2005) is the transcription factor
NFI-A, a CCAAT-related binding protein controlling genes in-820 Cell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc.volved in cell growth control, which has been shown to bind
sequences related to theonesofC/EBPa (Gronostajski, 2000).
Here we show that both C/EBPa and NFI-A bind the re-
gion responsible for miR-223 upregulation upon RA treat-
ment. Nevertheless, the binding of the two proteins on the
miR-223 promoter is mutually exclusive of the upregulation
following RA treatment, requiring release of NFI-A and bind-
ing of C/EBPa. Notably, our results indicate that NFI-A is
negatively controlled by miR-223, thus explaining how sus-
tained expression of the miRNA could be maintained during
granulocytic differentiation. Our findings point to miR-223
and NFI-A as novel and crucial players in the molecular cir-
cuitry controlling human granulopoiesis.
RESULTS
miR-223 Expression Is Associated with Myelopoiesis
Probes for miR-223, miR-181a, and miR-142-5, the hu-
man counterparts of the murine miR-223, miR-181, and
miR-142s species (www.sanger.ac.uk/Software/Rfam/mirna/
index.shtml), have been utilized to study the hematopoietic
lineage specificity of the corresponding RNAs. Figure 1A
shows that, in analogy to the murine model, miR-142-5 was
widely expressed in all hematopoietic cells and miR-181a
was detectable in bone marrow (BM) CD34+ progenitor cells
and in T lymphocytes (Chen et al., 2004). miR-223, however,
was absent in B and T lymphocytes and present in BM cells,
with the highest levels in the BM CD34 fraction, mostly rep-
resentative of lineage-committed precursors and mature he-
matopoietic cells. It should be considered that about 4% of
the BM nucleated cell population is constituted by CD34+
stem/progenitor cells and lineage-committed precursor cells
(Barnett et al., 1999). The majority of the CD34 cells are rep-
resented by myeloid cells (60%–75% of total nucleated cells)
at different stages of neutrophilic differentiation, with a ratio of
3:1 to erythroid cells. This evidence, together with the detec-
tion of miR-223 at high levels in mononucleated cells from
peripheral blood (Figure 1A, lane MNC) consisting of 50%–
70% of mature granulocytes, indicated an association of
miR-223 expression with this differentiation lineage.
miR-223 Induction Is Associated with Granulocytic
Differentiation of Myeloid Precursors Induced by RA
Myeloid differentiation can be induced in APL cells by treat-
ment with RA in vitro and in vivo. miR-223, miR-181a, and
miR-142-5 were all detectable in untreated peripheral-blood
cells from two newly diagnosed APL patients (Figure 1B,
lanes 0). miR-223 was strongly induced by RA and reached
a maximal expression at 72 hr of treatment either in vivo, in
cells isolated at different times from a patient (lane group
N1) receiving combined treatment of RA plus chemotherapy
(Mandelli et al., 1997), or in cells isolated from a second
patient and treated in vitro with RA (lane group N2). In addi-
tion, the three miRNA species were all detectable in the APL
cell line NB4 (Lanotte et al., 1991). Also, in these cells, the
addition of RA induced a marked and selective increase of
miR-223 starting at 24 hr after treatment and increasing pro-
gressively up to 72 hr (Figures 1C and 1D). The ubiquitous
miR-15a and miR-16, utilized as controls, did not show any
variation upon RA addition. No expression of miR-223 was
observed in the nonhematopoietic cervical carcinoma cell
line, HeLa (Figure 1C), or in medulloblastoma or neuroblas-
toma cell lines treated with RA (data not shown). These find-
ings indicated the specificity of miR-223 upregulation in RA-
induced granulocytic differentiation of leukemic cells.
In APL blasts, the effect of RA on granulocytic differentia-
tion is mediated by the PML/RARa fusion product. We there-
fore measured miR-223 expression levels in two non-APL
AML cell lines before and after treatment with RA. HL60 is
an AML cell line that expresses a functional RARa known
to mediate the RA effect on granulocytic differentiation (Col-
lins et al., 1990). As the NB4 precursor cells, HL60 are able
to undergo either myeloid or monocytic differentiation. On
the other side, Kasumi-1 is an AML cell line containing the
t(8;21) known to be resistant to the effect of RA on granulo-
cytic differentiation. Figure 1D shows that miR-223 was
strongly induced by RA addition in HL60 but not in Ka-
sumi-1 cells. Notably, miR-223 levels were not significantly
modified in two RA-resistant subclones: the NB4-MR4 de-rived from NB4 (lane group NB4-MR4) and the HL60-R de-
rived from HL60 (lane group HL60-R). These resistant cell
lines carry mutations abrogating RA binding capacities of
PML/RARa and RARa, respectively (Shao et al., 1997).
Densitometric analysis of the different gels indicated that,
in all tested cells, the upregulation of miR-223 ranged be-
tween 3- and 5-fold.
To assess the hematopoietic lineage specificity of miR-
223 induction, we studied whether miR-223 could be acti-
vated in HL60 and NB4 cells in response to vitamin D3,
which is known to induce APL cell differentiation toward
the monocytic lineage. While the expression of the mono-
cytic surface marker CD14 was induced by this treatment
in both cell lines (data not shown), vitamin D3 had no effect
in activating miR-223 transcription (Figure 1E).
Altogether, these data indicated that miR-223 accumula-
tion is an event specifically induced by RA during granulo-
cytic differentiation of myeloid cells, which occurs indepen-
dently of the expression of the PML/RARa fusion product.
C/EBPa Binding Sites Are Present on the miR-223
Promoter and Are Necessary for RA Induction
By scanning the miR-223 promoter with the TransFac
software package (http://www.gene-regulation.com/pub/
programs.html), two putative C/EBPa binding sites were
identified upstream of the region encoding the pre-miR-223
sequence (see schematic representation in Figure 2A). Since
C/EBPa is a key factor for the commitment of hematopoietic
cells to granulocytic lineage (Tenen, 2003), we investigated
the timing of C/EBPa induction by RA in relation to miR-
223 expression (see Figure S1 in the Supplemental Data
available with this article online). As previously reported in
both NB4 and HL60 cells (Radomska et al., 1998), wild-
type p42 isoform of C/EBPa was already present in NB4
cells, and its levels increased slightly at early times of RA
treatment (12 hr) and decreased to control levels at 48 hr.
Note that the levels of the p30 truncated isoform of
C/EBPa (Pabst et al., 2001) known to inhibit DNA binding
and transactivation activity of wild-type C/EBPa were un-
changed. It was previously suggested that the APL-associ-
ated PML/RARa fusion product interferes with the C/EBPa
function, thereby leading to an arrest in these cells at the pro-
myelocytic stage (Tenen, 2001): even if the protein was pres-
ent in promyelocytic cells, its binding to target genes either
was very poor (Duprez et al., 2003) or did not correlate
with transcriptional activation (Khanna-Gupta et al., 2003).
On the contrary, treatment with RA, in addition to inducing
C/EBPa expression, restored its binding activity and its cor-
rect nuclear distribution and increased its transactivation
function (Radomska et al., 1998; Tenen, 2001). Thus, it ap-
pears that upregulation of C/EBPa by RA precedes miR-223
activation in these cells.
In order to analyze whether the putative C/EBPa binding
sites are involved in RA induction, we made several con-
structs in which different portions of the miR-223 promoter
were fused to the coding region of miR-126, which is not ex-
pressed in myeloid cells (Figure 2B, lane group NT). Con-
structs I, II, III, and IV contain 76, 620, 810, and 1070Cell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc. 821
Figure 2. Mutational Analysis of the miR-
223 Promoter
(A) Schematic representation of the reporter con-
structs. The indicated portions of the miR-223
promoter, numbered relative to the 50 end of the
pre-miR-223 (indicated as a dashed box), were
fused to the region containing the pre-miR-126
sequence (black boxes). The putative binding
sites for CEBPa and NFI-A (from 709 bp
to 730 bp) are indicated by a gray box.
(B) Northern analysis of miR-126 and miR-223
expression in NB4 cells transfected with the re-
porter constructs and either untreated (lanes )
or treated with RA for 48 hr (lanes +). Thirty micro-
grams of total RNA was loaded on each lane. Hy-
bridizations were normalized for the endogenous
U6 snRNA. For miR-223 and U6, shorter expo-
sures are shown in comparison to miR-126; the
accumulation levels of this RNA are particularly
low due to the inefficient transfection of NB4
cells.
(C) The graph shows the +RA/RA ratios of miR-
126 levels relative to the +RA/RA ratios of the
endogenous miR-223 levels. Error bars repre-
sent standard deviation and were obtained from
three independent experiments.nucleotides upstream of the pre-miR-223, respectively,
while the miR-126 coding region contains the pre-miR-
126, including the Drosha processing sites (Figure 2A).
This region was previously shown to direct correct excision
of a mature miR-126 when cloned downstream of a heterol-
ogous RNA pol II promoter (data not shown). After transfec-
tion with the chimeric constructs, half of the NB4 culture was
treated with RA for 48 hr, and half was maintained without
the inducer for the same time. Figure 2B shows that con-
structs I and II did not induce miR-126 transcription upon
RA treatment. On the contrary, constructs III and IV, contain-
ing the putative C/EBPa sites, displayed a specific activation.
Interestingly, the degree of induction of these constructs
upon RA treatment was similar to that of the endogenous
miR-223 (Figure 2C). No significant difference was observed
between constructs III and IV, indicating that the region up-
stream of the C/EBPa sites does not contribute to this induc-822 Cell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc.tion. These results indicated that the region containing the
C/EBPa binding sites is necessary for miR-223 responsive-
ness to RA.
RA Treatment Recruits C/EBPa on the miR-223
Promoter Region
We next investigated whether C/EBPa physically interacts
with the miR-223 promoter and whether its binding corre-
lates with miR-223 transcriptional upregulation. This associ-
ation was analyzed in vivo during RA-induced granulopoiesis
of NB4 and RA-resistant NB4 cells by chromatin immunopre-
cipitation (ChIP) experiments (Figure 3). Cells were treated
with RA for 4, 24, 48, and 72 hr, and chromatin fragments
were immunoprecipitated with an anti-C/EBPa antibody.
DNA from the immunoprecipitates was then amplified by
PCR using primers (Oligos#1) located in the promoter region
close to the putative C/EBPa binding sites (see schematic
Figure 3. ChIP Analysis of the miR-223 Promoter
NB4 and NB4-MR4 cells were grown for the indicated times in the presence of 1 mM RA. Lanes 0 are untreated cells. Chromatin was immunoprecipitated
with anti-C/EBPa (panels C/EBPa) or anti-NFI-A (panels NFI-A) antibodies, and the recovered DNA was PCR amplified with the Oligos#1 and Oligos#2 cou-
ples of primers. The location of these primers (Oligos#1,1030/810 and Oligos#2,1400/1200 with respect to the 50 end of the pre-miR-223) is shown
in the upper panel together with the sequence of C/EBPa and NFI-A binding sites. Control amplifications were carried out on input chromatin before im-
munoprecipitation (rows Input) and on mock-immunoprecipitated chromatin (rows No-Ab). The right panel shows histograms of the quantitative real-
time PCR performed with Oligo#1 on chromatin of NB4 and NB4-MR4 cells at different times after RA treatment. Error bars represent standard deviation.representation in Figure 3). C/EBPa was found associated
with this region after 24, 48, and 72 hr of RA induction in
NB4 cells (lanes NB4 24, 48, and 72), whereas no reactivity
was measurable in untreated cells (lane 0) or after 4 hr of
RA treatment (lane 4). In NB4-MR4 cells, C/EBPa was not
detectable throughout all the RA treatment, with only a faint
reactivity at 72 hr (lane group NB4-MR4). These results
were confirmed also by quantitative PCR (right panel).
The specificity of C/EBPa occupancy in the region recog-
nized by Oligos#1 was indicated by the detection of signals
close to background levels when sequences located further
upstream (Oligos#2) were amplified in the same chromatin
preparations.
These experiments showed that, in APL cells, C/EBPa in-
teracts in vivo with the miR-223 promoter and that this bind-
ing correlates with both miR-223 upregulation and response
of these cells to RA.
NFI-A Competes with C/EBPa for Promoter Binding
Among the hundreds of predicted regulatory targets of miR-
223 (Lewis et al., 2005; Krek et al., 2005), we noticed tran-
scription factor NFI-A, a protein known to bind sequences re-
lated to the ones of C/EBPa (Gronostajski, 2000). Notably,
a search in the miR-223 promoter revealed the presence of
a NFI-A site (Meisterernst et al., 1988; Garlatti et al.,1993)
overlapping one of the two identified C/EBPa binding sites
(see Figure 3).To analyze the association of NFI-A with the miR-223 pro-
moter region, ChIP analysis was carried out with antibodies
against the NFI-A factor in the same conditions utilized for
C/EBPa. The immunoprecipitated DNA was amplified with
the same couples of primers as in the previous experiment.
In contrast to C/EBPa, NFI-A showed a strong interaction
with the region amplified with Oligos#1 in the absence of
RA. After RA treatment, its interaction gradually disappeared
with an inverse correlation to the binding of C/EBPa (Figure
3, lane group NB4 and right panel). Also in this case, signals
close to the background were obtained with Oligos#2, indi-
cating that the interaction of NFI-A is specifically limited to
the same region of C/EBPa. Interestingly, in RA-resistant
NB4-MR4 cells, NFI-A remains on the promoter even after
RA treatment (Figure 3, lane group NB4-MR4). These re-
sults correlated the RA activation of the miR-223 promoter
with the physical replacement of NFI-A by the C/EBPa
factor.
NFI-A Is a Bona Fide Target of miR-223
In order to find out whether NFI-A is a miR-223 target, we ini-
tially analyzed the levels of the NFI-A protein and mRNA be-
fore and after RA treatment of NB4 cells. Figure 4 shows
that, while the amount of the NFI-A protein decreased with
time after RA treatment, reaching low levels after 72 hr (Fig-
ure 4B), the accumulation of the mRNA was unaffected (Fig-
ure 4A). These are typical features for a miRNA target. InCell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc. 823
Figure 4. NFI-A Is a miR-223 Target
NB4 and NB4-MR4 cells were grown for the indicated number of hours in the presence of 106 M RA; lanes 0 are untreated cells.
(A) Total RNA was analyzed by real-time PCR with oligos for the NFI-A mRNA. Error bars represent standard deviation.
(B) Total proteins were analyzed by Western blot with anti-NFI-A antibodies (panel NFI-A). Control Western analysis of b-tubulin was performed as a loading
control (panel b-tubulin). NFI-A values were analyzed by densitometric scanning and reported in the histogram after normalization with b-tubulin.
(C) The renilla luciferase coding region is transcribed under the control of the TK promoter of HSV and the poly(A) site of SV40. The 30UTR of NFI-A is shown
as a black box. The sequences shown below indicate the putative miR-223 target site on the wild-type 30UTR (construct 30NFI-Awt), its mutated derivative
(construct 30NFI-Amut), and the pairing regions of miR-223.
(D) Plasmid psiU-223 contains the U1 snRNA gene promoter and terminator (psiUx, Denti et al., 2004) driving the expression of a pre-miR-223, including the
Drosha processing sites. In the insert, the expression of psiU-223 in HeLa cells is shown (lane, untransfected cells; lanes +, cells transfected with psiU-223).
(E) Cells were transfected with psiU-control and 30NFI-Awt (white box, 30NFI-Awt), psiU-223 and 30NFI-Awt (black box, 30NFI-Awt), and psiU-223 and 30NFI-
Amut (black box, 30NFI-Amut). The histogram indicates the levels of luciferase in the different transfected cells. Error bars represent standard deviation and
were obtained from three independent experiments.order to validate the NFI-A mRNA as a possible miR-223 tar-
get, we set up an assay in which the 30UTR of the NFI-A
gene, including the putative miRNA target site, was inserted
downstream of a luciferase ORF (30NFI-Awt, Figure 4C).
A construct containing a mutated sequence of the miRNA
binding site, 30NFI-Amut, was also produced as a control.
The different luciferase constructs were transfected into
NB4 cells with a plasmid carrying a constitutive-expression
cassette for miR-223 (psiU-223, Figure 4D) or with the
same vector expressing an unrelated 21 nucleotide RNA
(psiU-control). In these experiments, we preferred utilizing
a construct expressing miR-223 under a heterologous and
constitutive promoter in order to have a constant level of ex-
pression. The ability of psiU-223 to direct the expression and
processing of a mature miR-223 is shown (Figure 4D). A spe-
cific negative effect on luciferase activity was observed in the824 Cell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc.presence of miR-223 on the wild-type substrate, while no re-
duction in luciferase activity was obtained when the target
site was mutated (Figure 4E). The decrease in luciferase ac-
tivity was similar to the translational repressor effect observed
for other miRNAs on their substrates (Poy et al., 2004). These
results indicated that NFI-A is a target of miR-223.
Ectopic Expression and Knockdown of miR-223
We next evaluated whether a stable ectopic expression of
miR-223 affected the differentiation status of NB4 cells. Thus,
the NB4 cell line was infected with a lentiviral vector contain-
ing a cassette for the constitutive expression of miR-223
derived from the psiU-223 construct (Lenti-223). Figure 5A
shows that the resulting expression level of miR-223 in NB4
infected cells (lane Lenti-223) was about twice the amount
of that measurable in wild-type NB4 (lane ) or in NB4
Figure 5. Ectopic Expression and Knockdown of miR-223
(A) Schematic representation of the lentiviral construct for miR-223 expression (Lenti-223) and Northern analyses of 3 mg of total RNA extracted from un-
infected NB4 cells () or NB4 cells infected with the empty vector or with Lenti-223 and incubated for 48 hr. Hybridization to the U6 snRNA is shown as
a loading control.
(B) Percentage of CD11b+ or CD14+ cells and expression levels of growth-factor receptors involved in myeloid differentiation (G-CSFr and GM-CSFr), mea-
sured by qRT-PCR analysis in NB4 cells ectopically expressing either the empty vector or Lenti-223. Error bars represent standard deviation and indicate the
average values of three culture replicates for each construct.
(C) Morphological analysis of NB4 cells 4 days after infection with the empty vector or Lenti-223.
(D) Northern blot hybridizations of 3 mg of total RNA extracted from untreated NB4 cells () or transfected with LNA oligos against miR-126 or miR-223 and
incubated for 48 hr.
(E) LNA-treated cells were incubated in the absence or in the presence of different concentrations of RA for 48 hr and analyzed as in panel B; the values
indicate the ratio of the percentage of RA-induced positive cells versus the percentage of noninduced positive cells. Error bars represent standard deviation
and indicate the average values of three culture replicates for each construct.Cell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc. 825
infected with the empty vector (lane Vector). We then mea-
sured by flow cytometry the expression levels of two markers
of myelomonocytic differentiation: CD11b and CD14.
CD11b is a surface marker of granulocytic and monocytic
cell differentiation, while CD14 specifically recognizes cells
of the monocytic lineage. Figure 5B shows that the expres-
sion levels of CD11b approximately doubled, whereas
those of CD14 remained at the levels measurable in NB4
cells infected with the empty vector. Furthermore, a specific
increase of the mRNA expression for the granulocyte col-
ony stimulating factor receptor (G-CSFr) was observed in
NB4 cells infected with Lenti-223, whereas no changes
for the granulocyte-macrophage colony stimulating factor
receptor (GM-CSFr) mRNA were detected. Ectopic expres-
sion of miR-223 also induced morphological changes in
NB4 cells, including chromatin condensation, decreased
nuclear/cytoplasmic ratio, appearance of a paranuclear
Golgi region, and primary granules, which are consistent
with their maturation (Figure 5C).
To better analyze the function of miR-223 in granulopoie-
sis, locked nucleic acid (LNA) oligonucleotides complemen-
tary to miR-223 were utilized in order to sequester the
miRNA in an inactive form (Lecellier et al., 2005). The LNA-
miRNA hybrids are thermally stable (Vester and Wengel,
2004) and are not melted in canonical denaturing gels; there-
fore, the depletion of the miRNA can be judged by the de-
crease in its hybridization signal in Northern blots. NB4 cells
transfected with anti-223 LNA showed a 2-fold decrease in
miR-223 levels when compared to control cells transfected
with LNA against miR-126, not expressed in these cells (Fig-
ure 5D). Figure 5E shows that the knockdown of miR-223
produced a 30%–40% reduction of CD11b while maintain-
ing the level of CD14 unaltered in the presence of two differ-
ent RA concentrations. Altogether, these data indicated that
the levels of miR-223 are crucial for controlling the differen-
tiation fate of promyelocytic precursors.
RNAi against C/EBPa and NFI-A
RNAi against C/EBPa and NFI-A was utilized in order to val-
idate the regulatory circuitry connecting the two transcrip-
tional factors with the expression of miR-223 and cell differ-
entiation.
NB4 cells were infected with lentiviral constructs express-
ing siRNAs against C/EBPa or NFI-A. Both constructs
proved effective in reducing the levels of the correspond-
ing target proteins (Figures 6A and 6B). The knockdown of
C/EBPa resulted in decreased levels of miR-223 only after
RA treatment, whereas the decrease of NFI-A resulted in re-
duced levels of miR-223 in the absence of RA (Figures 6A
and 6B). In agreement with ChIP analysis, these data indi-
cated that both transcriptional factors function as miR-223
activators and that, in particular, C/EBPa is required for
miR-223 expression following RA treatment, while NFI-A
acts before induction. Notably, in comparison to mock-
infected cells, the knockdown of C/EBPa decreased the
effect of RA on granulocytic differentiation (both at 108 M
and 106 M RA), as judged by immunological phenotyp-
ing and morphological analysis (Figures 6C and 6D, lanes826 Cell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc.siC/EBPa). On the contrary, the reduction of NFI-A had an
opposite effect and strongly increased the differentiation
status of RA-treated NB4 cells (Figures 6C and 6D, lanes
siNFI-A). Altogether, these data indicated that sustained lev-
els of C/EBPa and reduced amounts of NFI-A are required
for myeloid differentiation. Moreover, these findings also pro-
vide evidence for NFI-A as a novel key regulator of granulo-
cytic differentiation.
DISCUSSION
It is now well accepted that miRNAs exert their function of
fine modulators of gene expression by controlling transla-
tional efficiency of a large number of target genes (Bartel,
2004). This regulation, as described in the cases studied
so far, is mainly involved in gene reprogramming occurring
during development and cell differentiation where fine tun-
ing, more than on/off regulation, provides the initial and sub-
tle changes of gene expression necessary to enter terminal
commitment.
In this study, we have identified in miR-223 an important
modulator of human myeloid differentiation. This RNA is spe-
cifically expressed in myeloid cells and is upregulated during
granulocytic differentiation of APL cells mediated in vivo or in
vitro by retinoic acid (RA). Interestingly, the same specificity
of induction was verified in blasts from patients undergoing
therapeutic treatment with RA, indicating that the effect
was not solely confined to in vitro-maintained cell lines.
The relevant role of miR-223 in the differentiation process
was demonstrated by both overexpression and knockdown
experiments. In the first case, doubling of the cells commit-
ted to the granulocyte-specific lineage was obtained,
whereas reduced miR-223 levels produced the opposite ef-
fect. Interestingly, the percentage of miR-223-infected cells
induced to differentiate into granulocytic lineage was similar
to that described for the ectopic expression of miR-181 in in-
ducing B-specific lymphoid lineage of mouse hematopoietic
precursors (Chen et al., 2004).
Study of miR-223 expression disclosed a very interesting
regulatory loop involving two well-known transcriptional fac-
tors, C/EBPa and NFI-A (see model in Figure 7). C/EBPa
was shown to interact with the miR-223 promoter region re-
quired for RA responsiveness, and its binding correlated per-
fectly in time with the start of miRNA induction. A variety of
studies in different experimental systems have provided com-
pelling evidence indicating a very important role of C/EBPa
in both growth arrest and terminal differentiation, in partic-
ular of granulocytes (Nerlov et al., 1998; Radomska et al.,
1998; Wang et al., 1999; Khanna-Gupta et al., 2001). Al-
though C/EBPa was known to induce granulopoiesis while
suppressing monocyte differentiation, it was unclear how
C/EBPa regulated this cell fate choice at the mechanistic
level.
The second miR-223 regulator, NFI-A, was initially de-
scribed as a CCAAT-box binding transcription factor, be-
longing to the nuclear factor I (NFI) family of proteins (Santoro
et al., 1988). The NFI family is composed of four independent
genes (NFI-A, -B, -C, and -X) and a large number of splice
Figure 7. A Model Summarizing the Interplay among miR-223, NFI-A, and C/EBPa in RA-Induced Granulocytic Differentiation
In undifferentiated NB4 cells (left panel), NFI-A binds the miR-223 promoter, keeping levels of miR-223 expression and consequently miR-223-mediated
translational repression low. Upon RA treatment (right panel), C/EBPa replaces NFI-A on the miR-223 promoter and boosts miR-223 expression. This
results in an increase of miR-223-mediated translational repression of the NFI-A mRNA and decrease of the NFI-A protein.
Figure 6. RNAi against C/EBPa and NFI-A
(A and B) NB4 cells were infected with an empty lentiviral vector (Vector) or lentiviral constructs expressing siRNAs against C/EBPa (siC/EBPa, [A]) or NFI-A
(siNFI-A, [B]). On the left of each panel, the Western analysis of 50 mg of proteins 48 hr after infection is shown. The antibodies utilized are indicated on the
side. b-tubulin detection is shown as a loading control. On the right of each panel, the Northern analysis of miR-223 expression is shown; cells were either
untreated () or treated (+) with RA for 48 hr. Hybridization to the endogenous U2 snRNA is shown as a loading control.
(C) CD11b+ or CD14+ cells were analyzed by FACS; the values indicate the ratio of the percentage of RA-induced positive cells to the percentage of non-
induced positive cells. Error bars represent standard deviation and indicate the average values of three culture replicates for each construct.
(D)Morphological analysisofNB4 cells infectedwith thedifferent constructsandeitheruntreated (control panels) or treatedwithdifferentdosesofRA for 4 days.Cell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc. 827
variants that form homodimers and heterodimers, thus creat-
ing an extensive network of possible functional dimers (Gro-
nostajski, 2000). The NFI proteins bind as dimers to the dyad
symmetric consensus sequence TTGGC(N5)GCCAA; never-
theless, they could also bind very well to individual half-sites,
even though with a reduced affinity, and presumably as het-
erodimers with other proteins (Meisterernst et al., 1988;
Bachurski et al., 1997). Due to the ability to bind to half-sites,
the NFI family could somehow compete with the C/EBP fac-
tors in binding the CCAAT element (Garlatti et al., 1993).
In line with this hypothesis, our experiments indicated a
very interesting functional interrelationship between NFI-A
and C/EBPa. One of the two C/EBPa binding elements in
the miR-223 promoter overlaps with a NFI-A binding site
(Meisterernst et al., 1988; Bachurski et al., 1997; Gronostaj-
ski, 2000). Indeed, NFI-A was shown to interact with this se-
quence in vivo; nevertheless, its binding was released upon
RA treatment and substituted by that of C/EBPa. This dis-
placement correlated with miRNA transcriptional upregula-
tion. Notably, in cells resistant to retinoic acid and unable
to undergo differentiation, the NFI-A factor remained on
the miRNA promoter and no C/EBPa binding was detected.
These findings supported the hypothesis of a competition
between the two proteins in the regulation of the miRNA pro-
moter: NFI-A produces low levels of miR-223, while C/EBPa
is the differentiation-specific activator. The activation by
C/EBPa had only a 3- to 5-fold effect on miR-223 levels, with
little variations in different clonal and primary cells, indicating
that granulocytic differentiation requires fine tuning of miRNA
expression. RNAi proved that NFI-A and C/EBPa do indeed
act as transactivators of miR-223 before and after RA treat-
ment, respectively. Interestingly, miR-223 activation corre-
lated in time with the decrease in accumulation of the NFI-A
protein, while its mRNA levels remained unaltered; this, to-
gether with the experimental validation of the bona fide target
site in the 30UTR, indicated that NFI-A is a target of miR-223.
Altogether, these data indicate that, in promyelocytic cells,
the retinoic-acid treatment induces activation of C/EBPa,
which in turn is able to displace NFI-A from the miR-223 pro-
moter, thus allowing its upregulation. In cascade, miR-223
acts by repressing NFI-A, thus subtracting it from the com-
petition with C/EBPa and maintaining sustained levels of
miR-223 expression. Besides their effect on miR-223, the
knockdown of both transcriptional factors had interesting
consequences on differentiation. RNAi against NFI-A drasti-
cally increased the differentiation response of NB4 cells to
RA, whereas the opposite effect was found with C/EBPa de-
pletion. These findings are in agreement with the roles de-
scribed for NFI-A and C/EBPa. C/EBPa has been implicated
in promoting differentiation and repressing genes that play
the important function of promoting growth (McKnight,
2001; Tenen, 2001). On the other hand, NFI-A has been im-
plicated in replication as well as in controlling changes in cell
growth (Gronostajski, 2000).
The regulatory circuitry described here provides another
example of how gene reprogramming during differentiation
relies on fine modulation of gene expression. It is also inter-
esting to note that the fine tuning of miR-223 expression is828 Cell 123, 819–831, December 2, 2005 ª2005 Elsevier Inc.part of an autoregulatory loop in which translational repres-
sion of the miRNA target allows the establishment of miRNA
sustained expression. Notably, the relevant function of miR-
223 upregulation would be not only the decrease of NFI-A-
mediated functions, which appear quite crucial, but also
the inhibition of other putative substrates not yet tested, pos-
sibly important for cell-lineage specification.
In conclusion, our study provides new insight into the un-
derstanding of the molecular processes required for granu-
locyte differentiation and offers the possibility of identifying
new reagents for the development of novel therapeutic ap-
proaches to leukemia.
EXPERIMENTAL PROCEDURES
Reagents
All-trans-retinoic acid was purchased from Sigma and utilized at a con-
centration of 1 mM unless differently specified. Vitamin D3 was a gift
from Dr. Klaus (Hoffmann-La Roche) and was utilized at a concentration
of 1 mM for 72 hr.
Cell Cultures
All cell lines were maintained in RPMI 1640 medium supplemented with
50 IU/ml of penicillin, 50 mg/ml streptomycin, and 10% fetal calf serum
(FCS).
Peripheral blood was obtained from two informed, newly diagnosed
APL patients (N1 and N2), classified as M3 or M3-variant by morpholog-
ical criteria according to the French-American-British (FAB) classification,
and presented an initial percentage of circulating blasts that was more
than 80%. Analysis of the PML/RARa fusion gene was performed by
RT-PCR as reported elsewhere (Lo Coco et al., 1992). Leukemic cells
were isolated on Ficoll-Hypaque density gradients and cultured in RPMI
1640 medium supplemented with 50 IU/ml of penicillin, 50 mg/ml strepto-
mycin, and 10% fetal calf serum (FCS) as described (Fazi et al., 2005).
CD34+ cells were isolated from the bone marrow of informed normal
donors by Ficoll-Hypaque density-gradient centrifugation, depletion of
adherent cells by adherence to plastic, and purification by immunomag-
netic separation (Miltenyi, Biotech) as recommended by the manufac-
turer. Flow cytometric analysis confirmed that more than 90% of the cells
were CD34+. Mature T and committed B lymphoid cells, kindly provided
by Prof. A. Santoni, were selected from peripheral blood according to Mit-
telstadt and Ashwell (1998) and Benjamin et al. (1996). 293T cells were
grown in Iscove’s modified Dulbecco’s medium (IMDM, GIBCO) supple-
mented with 10% FBS and L-glutamine (50 U/ml), penicillin, and strepto-
mycin (50 U/ml).
RNA Extraction and Analysis
Total RNA from cells was extracted using TRIzol RNA isolation system (In-
vitrogen) according to the manufacturer’s instructions. For Northern anal-
ysis of miRNAs, total RNA was electrophoresed in a 10% polyacrylamide
7 M urea gel and transferred by electroblotting onto Hybond-N+ mem-
brane (Amersham Pharmacia Biotech). Hybridization was performed
with terminally 32P-labeled DNA oligos. Probes were as follows: a-223,
50-GGGGTATTTGACAAACTGACA-30; a-181a, 50-ACTCACCGACAGC
GTTGAATGTT-30; a-142-5, 50-GTAGTGCTTTCTACTTTATG-30; a-126,
50-AGCATGGCACTCATTATTACG-30; a-16, 50-CGCCAATATTTACGTG
CTGCTA-30; a-15a, 50-CACAAACCATTATGTGCTGCTA-30. The endog-
enous U2 snRNA was detected with oligo U2R, 50-GGGTGCACCGTTCC
TGGAGGTAC-30 and U6 snRNA with oligo U6, 50-TGTGCTGCCGAAGC
AAGCAC-30.
RNA quantification was performed by real-time PCR in ABI PRISM
7000 Sequence Detection System (Applied Biosystems). TaqMan oligo-
nucleotides (Assay on Demand) for NFI-A, colony stimulating factor 3 re-
ceptor (CSF3r or G-CSFr), colony stimulating factor 2 receptor (CSF2r or
GM-CSFr), and GAPDH were purchased from Applied Biosystems and
used as recommended by the manufacturer. Delta-delta Ct values were
normalized with those obtained from the amplification of a GAPDH. All re-
actions were performed in triplicate.
Immunoblot Analysis
Total cell extracts (50 mg of proteins) were fractionated by electrophoresis
on 10% SDS polyacrylamide gel, electroblotted to nitrocellulose mem-
brane (Protran, S&S) and reacted with anti-NFI-A (Abcam) or anti-
C/EBPa (Santa Cruz) antibodies. Immunoreactivity was determined using
the ECL method (Amersham) with the reagents provided according to the
manufacturer’s instructions.
Formaldehyde Crosslink and Chromatin Immunoprecipitation
Assay
Crosslinking of proteins to DNA was obtained by the direct addition to cul-
tured cells (2  106) of formaldehyde at 1% final concentration for 10 min
at 37ºC. After sonication, chromatin was immunoprecipitated overnight
with 5 ml of the antibodies anti-C/EBPa (Santa Cruz) and anti-NFI-A
(Abcam) as described (Fazi et al., 2005). Genomic regions of about 200
bp close to putative CEBPa binding sites as indicated by a search per-
formed using the MatInspector Professional and Alibaba2 software pro-
grams on a region further upstream of the miR-223 promoter (1300 bp
upstream of miR-223) were amplified with the following primer sequences
designed by the Primer Express software (Applied Biosystems): oligo#1
(forward), 50-GCCCTCTTTGTTGATGTGTC-30; oligo#1 (reverse), 50-GG
CAGCTATTAAAGTGCCCT-30; oligo#2 (forward), 50-CTTGCTGAAAGAC
AAGGCTG-30; and oligo#2 (reverse), 50-CTGGTGTCAAATTACTGCCC-
30, as described (Fazi et al., 2005). Quantization of coimmunoprecipitated
promoter fragments was performed in triplicate using the SYBR green dye
detection method with Oligos#1. Delta-delta Ct values of each immuno-
precipitated sample were normalized with those obtained from the ampli-
fication of their respective input and by subtracting the values obtained
in the corresponding samples with normal rabbit serum as described
(Chakrabarti et al., 2002).
Promoter Analysis
A DNA fragment containing the pre-miR-126 molecule (51 bp to +34 bp
relative to the mature miR-126) was amplified and cloned in pBluescript
(Stratagene). DNA fragments from 76 bp to 25 bp (clone I), 620 bp
to 25 bp (clone II), 810 bp to 25 bp (clone III), and 1070 bp to
25 bp (clone IV) relative to the pre-miR-223 were inserted upstream of
the pre-miR-126 fragment. In all constructs, a 240 bp fragment derived
from the 30 downstream region of miR-223 was cloned downstream of
the pre-miR-126 fragment. These plasmids (20mg) were individually trans-
fected by electroporation into NB4 cells. After 3 hr, cells were divided in
two, and one aliquot was treated with RA for 48 hr. Total RNA from RA-
treated and untreated cells was extracted and analyzed by Northern blot
as described above. Quantitation was done using an InstantImager
(Packard).
Assay of Luciferase Activity
The 30UTR of the human NFI-A gene was PCR amplified using the primers
50-CGCTCTAGACATGGACGCAACCTCAACCCAG-30 and 50-ATTTGCG
GCCGCTCAGTTTTTAAAGGGATACAAG-30 and cloned downstream of
the stop codon in pRL-TK (Promega), giving rise to 30NFI-Awt plasmid.
This construct was used to generate the 30NFI-Amut plasmid. NB4 cells
were transfected by electroporation with 10 mg of pRL-TK derivative
(Rr-luc), 1 mg of pGL3 control vector (Pp-luc, Promega), and 10 mg of
psiU-223 or psiU-control. Cells were harvested 24 hr posttransfection
and assayed with Dual Luciferase Assay (Promega) according to the man-
ufacturer’s instructions.
Plasmid Constructs and miRNA Knockdown
The psiU-223 plasmid was generated by cloning a fragment containing
the pre-miR-223 (from 56 bp to +71 bp relative to the 50 end of miR-
223) in the psiUx plasmid, as described by Denti et al. (2004). The psiU-
control contains an artificial short hairpin sequence producing a 22 nucle-
otide RNA (50-CAACAAUUGUGCAGCCUGGCUU-30). The constructs forRNAi were also raised in psiUx; they transcribe a short hairpin that produ-
ces the accumulation of siRNAs against the sequence 50-GAACAGCAAC
GAGTACCGG-30 of C/EBPa and 50-GTTTTGACAGAAACTGACAGG-30
of NFI-A. The psiU-derived expression cassettes were subcloned into the
EcoRV site or in the LTR of the lentiviral vector pRRLcPPT.hPGK.EGFP.
WPRE (Bonci et al., 2003). Infective particles were produced as already
described (Bonci et al., 2003).
LNA oligonucleotides against miR-223 and miR-126 were obtained
from Exiqon (www.exiqon.com). Knockdown oligos were individually
transfected by Lipofectamine 2000 (Invitrogen) into NB4 cells at a final
concentration of 40 nM together with 10 nM of a FITC-labeled LNA oligo-
nucleotide against an A. thaliana miRNA. After 48 hr, transfected cells
were isolated by FACScan flow cytometer, and differentiation and miRNA
levels were analyzed. Before loading on polyacrylamide 7 M urea gels,
RNA samples were treated at 65ºC in 3.5 M urea.
Immunophenotyping and Morphological Analysis
Cell differentiation was evaluated by direct immunofluorescence staining
using allophycocyanin (APC) conjugated mouse anti-human CD11b and
peridinin chlorophyll protein (PerCP) conjugated mouse anti-human
CD14 cell-surface myeloid-specific antigens (BD Biosciences, San Jose,
CA). A minimum of 50,000 events were collected for each sample by
a FACScan flow cytometer (Becton Dickinson) using CellFit software
(Becton Dickinson) for data acquisition and analysis. Morphology was
evaluated after 4 days of treatment in conventional light-field microscopy
of Wright-Giemsa-stained cytospins.
Supplemental Data
Supplemental Data include one figure and can be found with this article
online at http://www.cell.com/cgi/content/full/123/5/819/DC1/.
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